Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, and Phosphonate-containing Agents), By Applications (Hypertension, Cardiovascular Diseases, Kidney Diseases, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis and Forecast till 2034

Angiotensin Converting Enzyme (ACE) Inhibitors Market was valued at US$ 3.8 billion in 2024 and is projected to grow at a CAGR of 5.6% to reach US$ 6.3 billion by 2034.

Angiotensin-converting enzyme (ACE) inhibitors are a class of medications used primarily for the treatment of high blood pressure (hypertension), scleroderma, migraines, and heart failure.

They work by blocking the production of angiotensin II, a substance that narrows blood vessels and raises blood pressure. By relaxing blood vessels, ACE inhibitors allow blood to flow more easily, thereby lowering blood pressure and reducing the workload on the heart.

ACE inhibitors are also used to treat or prevent other conditions, including coronary artery disease, diabetic kidney disease as well as certain chronic kidney diseases. The angiotensin-converting enzyme (ace) inhibitors market is seen significant growth in investments in the past decade which has led to the discovery of several novel active compounds that are effective in lowering blood pressure.

Most ACE inhibitors in the angiotensin-converting enzyme (ace) inhibitors market work by blocking the activity of the angiotensin-converting enzyme, which plays a role in the renin-angiotensin-aldosterone system (RAAS). By inhibiting this enzyme, ACE inhibitors reduce the production of angiotensin II, a hormone that causes blood vessels to constrict, leading to lowered blood pressure.Most medications in the angiotensin-converting enzyme (ace) inhibitors market have common side effects including cough, dizziness, headache, fatigue, and drowsiness. Some people may also experience allergic reactions, hyperkalemia (high potassium levels), or changes in kidney function. Persistent cough is a well-known side effect that may necessitate discontinuation of the medication.

Approximately 5% of persons aged 20 and above have CAD according to reports by the Centre for Disease Control and Prevention (CDC). The most prevalent kind of heart disease in the US is coronary artery disease, which affects over 20.5 million adult Americans. Heart disease claimed the lives of about 695,000 Americans in 2021, accounting for 1 in 5 fatalities.

Increasing cases of cardiovascular disorders across the globe will lead to a demand for preventive and curative medication with minimal side effects. This will propel the angiotensin-converting enzyme (ace) inhibitors market on an upward trajectory throughout the upcoming forecast period.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Drivers of the Angiotensin Converting Enzyme (ACE) Inhibitors Market:      

• Rising prevalence of cardiovascular diseases (CVDs): There has been a rapid rise in the number of cases of coronary artery disorders across the world in the last two decades. This is partly due to the increasingly hectic lifestyles, poor health habits, and increased stress these are major drivers as ACE inhibitors are a well-established and effective treatment for these conditions. The prevalence of hypertension alone is expected to reach 1.5 billion people by 2025, according to the World Health Organization.
• Growing geriatric population: As the population ages, there is a greater demand for medications to treat chronic conditions like hypertension and heart failure, which are more common in older adults. Angiotensin angiotensin-converting enzyme (ACE) Inhibitors Market is expected to witness growth in the upcoming years.
• Increased awareness of cost-effective preventive healthcare:  There is a growing emphasis on preventive healthcare and early intervention for chronic diseases. ACE inhibitors are generally a relatively inexpensive medication, which makes them an attractive option for patients and healthcare systems alike. This leads to more people being diagnosed and treated for hypertension and other conditions that can benefit from ACE inhibitors leading to more demand in the angiotensin-converting enzyme (ace) inhibitors market.
• Established safety and efficacy profile: ACE inhibitors have a long history of safe and effective use in managing cardiovascular and renal diseases. This well-established track record makes them a trusted option for both doctors and patients.

Restrains in the Angiotensin Converting Enzyme (ACE) Inhibitors Market:

• Competition from Alternative Therapies: The presence of other effective blood pressure medications, such as angiotensin II receptor blockers (ARBs), calcium channel blockers, and diuretics, gives physicians a wider range of treatment options.
• Side Effects: While generally well-tolerated, ACE inhibitors can cause side effects such as dry cough, dizziness, and low blood pressure. This can lead to medication non-adherence, which is a challenge in managing chronic conditions.
• Patent Expiry: Many of the leading ACE inhibitor medications are off-patent, which has increased competition from generic drugs. This can drive down the overall market revenue for branded ACE inhibitors and setback the angiotensin-converting enzyme (ACE) Inhibitors Market.

Key Opportunities in Angiotensin Converting Enzyme (ACE) Inhibitors Market:

•  Expanding Treatment Guidelines:  Medical guidelines for hypertension and heart failure are increasingly recommending the use of ACE inhibitors. This is due to the strong evidence base supporting the efficacy and safety of these drugs.
• Focus on Patient Compliance:  Pharmaceutical companies are developing new ACE inhibitor formulations that are designed to improve patient compliance. These include long-acting formulations that require less frequent dosing and fixed-dose combinations that combine ACE inhibitors with other medications.
• Development of Novel ACE Inhibitors: Research is ongoing to develop new ACE inhibitors with improved efficacy and safety profiles. For example, some researchers are developing ACE inhibitors that are tissue-specific, which could reduce side effects.
• Combination Therapies: ACE inhibitors are often used in combination with other medications to treat hypertension and CVDs. The development of new combination therapies could create new opportunities for the ACE inhibitor market.

Angiotensin angiotensin-converting enzyme (ACE) Inhibitors Market is segmented based on based on by Type, by Technology and Region.

Type Insight

• Sulfhydryl-containing Agents- This is a mature segment expected to show steady revenue shares since it has been available for longer in the market. It consists of captopril one of the most popular ACE inhibitor drugs.
• Dicarboxylate-containing Agents- This is currently the largest segment of the angiotensin-converting enzyme (ace) inhibitors market revenue-wise. It will continue to lead the market in the future due to the wide range of medications available that cater to different patient needs.
• Phosphonate-containing Agents- This is a growing segment that will witness the fastest growth rates in the future due to the potential increase in efficacy and mitigation of side effects delivered by these.

Application Insights

• Hypertension is the largest application-based segment of the angiotensin-converting enzyme (ace) inhibitors market which will continue holding the dominant revenue shares of the market in the future.
• Cardiovascular Diseases- This is the second largest segment of the market catering to a wide range of heart disease-related symptoms. The rising incidence of different CVD and the need to mitigate the adverse effects of CAD will drive this segment
• Kidney Diseases- This is a growing segment of the target market driven entirely by the increasing incidence of chronic kidney disorders.
• Other- This is a niche segment of the Angiotensin Converting Enzyme (ACE) Inhibitors Market catering to migraines and sclerodermas.

Regional Insights:

Angiotensin Converting Enzyme (ACE) Inhibitors Market Regional Insights:

On region the Angiotensin Converting Enzyme (ACE) Inhibitors Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America market currently holds the dominant market shares of the Angiotensin Converting Enzyme (ACE) Inhibitors Market and is expected to lead throughout the forecast period due to the high prevalence of chronic diseases leading to more curative approaches. Advanced healthcare infrastructure with well-equipped hospitals and a strong presence of leading pharmaceutical manufacturers are other major growth drivers.
• Asia Pacific region is the second largest regional market projected to witness a significant growth rate in the forecast period due to factors like rising disposable incomes, increasing government investments in healthcare, and a rapidly growing geriatric population. An increase in the number of cases of CVD and kidney disorders will drive market growth.
• Europe has a mature angiotensin-converting enzyme (ACE) Inhibitors Market with a strong focus on product quality and ergonomic design that allows rapid treatment. Stringent regulations and high healthcare spending further contribute to market growth.
• Latin America region is expected to show steady growth due to developing healthcare sectors, improved access to medical equipment and health tech, and increasing awareness about the benefits of ACE inhibitors.
• Middle East & Africa: The Angiotensin Converting Enzyme (ACE) Inhibitors Market in this region is expected to witness significant growth in the coming years, driven by several factors such as the rapidly growing awareness regarding the benefits of these pharmaceuticals with regards to diagnostic accuracy and efficient patient-oriented care.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the Angiotensin Converting Enzyme (ACE) Inhibitors Market report based on By Type, By Technology and Region:

Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Type:

• First Generation
• Second Generation
• Third Generation

Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Technology:

• Hypertension
• Cardiovascular Diseases
• Kidney Diseases
• Other

Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Angiotensin Converting Enzyme (ACE) Inhibitors Market includes Pfizer Inc., Novartis AG, Merck & Co. Ltd., Astra Zeneca Pharmaceuticals LP, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Co., Bayer AG, GSK LLC, Johnson & Johnson, Teva Pharmaceutical Inc.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

• In May 2021, Novartis declared that the FDA had approved Entresto, a novel ACE inhibitor medication, for the management of heart failure. It has been demonstrated that this medication lowers the risk of hospitalization and death in heart failure patients.
• In November 2020, Pfizer and BioNTech revealed the 95% efficacy of the COVID-19 vaccination in their clinical trial results in November 2020. Being a top manufacturer of ACE inhibitors, Pfizer has benefited greatly from the COVID-19 vaccine's success.

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
• Merck & Co., Ltd.
• Astra Zeneca Pharmaceuticals LP
• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb Co.
• Bayer AG
• GSK LLC
• Johnson & Johnson
• Teva Pharmaceutical, Inc.

“*” marked represents similar segmentation in other categories in the respective section.